Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection.

Respiratory syncytial virus (RSV) infection is often associated in infancy with life-threatening bronchiolitis, which is also a major risk factor for the development of asthma. At present, no effective prophylaxis is available against RSV infection. Herein, we describe an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres (IGT), containing a cocktail of plasmid DNAs encoding all RSV antigens, except L. A single administration of IGT (25 microg/mouse) induces expression of the mRNA and proteins of all antigens in the lung and results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. IGT-administered mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Furthermore, IGT results in significant induction of RSV-specific IgG antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and interferon-gamma production in the lung and splenocytes compared with controls. Together, these results demonstrate the potential of IGT against acute RSV infection.

[1]  H. Moll,et al.  Treatment and prevention of respiratory syncytial virus infection , 2000, European Journal of Pediatrics.

[2]  M. Parrington,et al.  Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. , 2000, Virology.

[3]  M. Otterlei,et al.  Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14. , 1994, Vaccine.

[4]  R. Lockey,et al.  Respiratory syncytial virus induces the expression of 5-lipoxygenase and endothelin-1 in bronchial epithelial cells. , 1998, Biochemical and biophysical research communications.

[5]  G. Taylor,et al.  Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. , 1987, Immunology.

[6]  C. Jun,et al.  Synergistic cooperation between water-soluble chitosan oligomers and interferon-gamma for induction of nitric oxide synthesis and tumoricidal activity in murine peritoneal macrophages. , 2000, Cancer letters.

[7]  H. Rosenberg,et al.  Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment , 1999, Clinical Microbiology Reviews.

[8]  B. Guy,et al.  Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. , 2001, Vaccine.

[9]  R. Lockey,et al.  Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. , 2001, Biochemical and biophysical research communications.

[10]  C. Bonville,et al.  Overnight titration of human respiratory syncytial virus using quantitative shell vial amplification. , 1998, BioTechniques.

[11]  G. Prince,et al.  Efficacy and Safety Studies of a Recombinant Chimeric Respiratory Syncytial Virus FG Glycoprotein Vaccine in Cotton Rats , 2000, Journal of Virology.

[12]  T. Tanimoto,et al.  Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. , 1999, Journal of immunology.

[13]  R. Lockey,et al.  Recurrent Respiratory Syncytial Virus Infections in Allergen-Sensitized Mice Lead to Persistent Airway Inflammation and Hyperresponsiveness1 , 2000, The Journal of Immunology.

[14]  C. Dupont,et al.  Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. , 1998, Immunity.

[15]  C. Mandl,et al.  A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. , 1999, Journal of immunology.

[16]  C. Long,et al.  Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group , 1991, Antimicrobial Agents and Chemotherapy.

[17]  M. Parrington,et al.  Protection against Respiratory Syncytial Virus Infection by DNA Immunization , 1998, The Journal of experimental medicine.

[18]  A. Osterhaus,et al.  Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development. , 2001, Vaccine.

[19]  B. Murphy,et al.  Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived , 1991, Journal of virology.

[20]  R. Lockey,et al.  Intranasal IFN-γ gene transfer protects BALB/c mice against respiratory syncytial virus infection , 1999 .

[21]  S. Davis,et al.  Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.

[22]  Lisbeth Illum,et al.  Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2) , 1994, Pharmaceutical Research.

[23]  J. de Braekeleer,et al.  Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. , 2003, International journal of pharmaceutics.

[24]  S. Mohapatra.  Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus , 2003, The Pediatric infectious disease journal.

[25]  R. Chanock,et al.  Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. , 1992, Pediatrics.

[26]  D. Chargelegue,et al.  Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-gamma. , 1998, International immunology.

[27]  B. Graham,et al.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. , 1991, The Journal of clinical investigation.

[28]  B. Moss,et al.  Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. , 1999, Vaccine.

[29]  J. Gerin,et al.  The Development of Balb/c Cells Persistently Infected with Respiratory Syncytial Virus: Presence of Ribonucleoprotein on the Cell Surface 1 , 1981, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[30]  P. Collins,et al.  Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins , 1990, Journal of virology.

[31]  C. Kaetzel,et al.  Intracellular neutralization of virus by immunoglobulin A antibodies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Hall.  Prospects for a respiratory syncytial virus vaccine. , 1994, Science.

[33]  J. Balsinde,et al.  Chitosan‐induced phospholipase A2 activation and arachidonic acid mobilization in P388D1 macrophages , 2000, FEBS letters.

[34]  G. Prince,et al.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections , 1995, Clinical microbiology reviews.

[35]  H. Tsujimoto,et al.  Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). , 2000, Vaccine.

[36]  R. Duncan,et al.  Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. , 1999, International journal of pharmaceutics.

[37]  D. Weiner,et al.  Modulating the immune response to genetic immunization , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[39]  I Saiki,et al.  Immunological activity of chitin and its derivatives. , 1984, Vaccine.